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Quantitative weight of evidence (QWoE) methodology utilizes detailed scoring sheets to assess the
quality/reliability of each publication on toxicity of a chemical and gives numerical scores for quality and
observed toxicity. This QWoE-methodology was applied to the reproductive toxicity data on diisono-
nylphthalate (DINP), di-n-hexylphthalate (DnHP), and dicyclohexylphthalate (DCHP) to determine if the
scientiﬁc evidence for adverse effects meets the requirements for classiﬁcation as reproductive toxicants.
The scores for DINP were compared to those when applying the methodology DCHP and DnHP that have
harmonized classiﬁcations. Based on the quality/reliability scores, application of the QWoE shows that
the three databases are of similar quality; but effect scores differ widely. Application of QWoE to DINP
studies resulted in an overall score well below the benchmark required to trigger classiﬁcation. For DCHP,
the QWoE also results in low scores. The high scores from the application of the QWoE methodology to
the toxicological data for DnHP represent clear evidence for adverse effects and justify a classiﬁcation of
DnHP as category 1B for both development and fertility. The conclusions on classiﬁcation based on the
QWoE are well supported using a narrative assessment of consistency and biological plausibility.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The process of hazard assessment and risk characterization
should include a science-based evaluation of all of the available
data on the investigation of the toxicity of a speciﬁc chemical
(Beronius et al., 2014; Lutter et al., 2015; Rhomberg, 2015; Schreider
et al., 2010; US-EPA, 2005). Traditionally, hazard assessments and
risk characterization have relied on scientiﬁc judgment with a
narrative assessment and have often only included results from
“key studies”. Consequently, the process has been criticized for lack
of objectivity and transparency (see for example, Myers et al.,
2009). However, conclusions based on the overall toxicity data-
base often require integration of several lines of evidence (different
types of studies) with different research objectives, applied meth-
odologies and study quality. The available database may include
peer-reviewed publications often addressing selected endpoints
with potential relevance to toxicity, but also reports on the results
of targeted toxicity testing following speciﬁc protocols required byy, University of Würzburg,
. Dekant).
Inc. This is an open access article ulegislation. In addition, the relevance of effects reported in scientiﬁc
publications may be controversial. Therefore, narrative assess-
ments have a number of weaknesses. To improve their quality,
weight of evidence (WoE) approaches are increasingly mandated in
chemical regulations (Agerstrand et al., 2014; ECHA, 2015; Weed,
2005). However, detailed guidance to perform WoE assessments
is lacking and quantitative aspects only received limited consider-
ations (Rhomberg, 2015; Van Der Kraak et al., 2014).
A recently developed quantitative weight of evidence (QWoE)
approach to assess toxicity data for chemicals is designed to assist
with classiﬁcation and labeling (C&L) regarding reproductive
toxicity endpoints (Dekant and Bridges, 2016). This QWoE applies
predeﬁned scoring criteria for relevant aspects of quality/reliability
of a study for all reported effects to provide a fully transparent
assessment. The scores representing strength of evidence for
adverse effects are then compared to benchmark scores that are
anchored to adverse biological endpoints and serve as the basic
requirements for classiﬁcation.
This QWoE was used to assess a need for C&L regarding ﬁndings
from reproductive toxicity studies of three phthalates, diiso-
nonlyphthalate (DINP), dicyclohexylphthalate (DCHP), and di-n-
hexylphthalate (DnHP). Phthalates are widely used as plasticizers.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Glossary of terms
Weight of evidence method (WoE) The identiﬁcation and
objective analysis (using
predeﬁned, scientiﬁcally
justiﬁed criteria) of all
potentially relevant
studies, for their quality
and in testing a
hypothesis (problem
formulation)
Quantitative weight of evidence (QWoE) The identiﬁcation,
objective analysis
and numerical
scoring (using
predeﬁned
scientiﬁcally
justiﬁed criteria) of
all potentially
relevant studies,
for both their
quality and
relevance in
testing a
hypothesis
(problem
formulation)
The hypothesis Generally, takes the form of “does chemical of
interest X cause adverse effects Y under
conditions Z”. Conditions may include
exposure levels and duration, species of
interest, adverse effects are deﬁned as by
WHO/IPCS
Endpoints The measured and modelled ﬁndings used to
identify and characterise adverse effects Y
Quality The reliance that can be placed on the ﬁndings of
each study for the purpose of critically testing the
hypothesis
Relevance The utility of the ﬁndings of each study on adverse
endpoints for the purpose of critically testing the
hypothesis
Lines of evidence The different types of investigation used to
critically test the hypothesis (e.g.
observations in man, targeted toxicity
testing in animals, in vitro experiments
determining molecular endpoints, and in
silico predictions of toxicity based on read-
across or quantitative structure activity
relationships)
Weighting of endpoints A multiplier that is applied to the
relevance/effect scores to reﬂect the
relative importance of different types
of endpoint and/or different lines of
evidence in supportof thehypothesis
Strength of evidence This score is derived by multiplying the
ﬁnal relevance/effects scores by the
quality/reliability score for a particular
study
Overall weight of evidence This is a summationof theﬁndings
from all suitable studies. It may be
presented graphically as a plot of
relevance/effects against quality
scores or as an average numerical
value with ranges
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has been replaced by higher molecular weight phthalates such as
DINP in many applications due to concerns regarding possible
adverse effects of DEHP-exposures in humans. A concern for
phthalates in general, with a focus regarding adverse reproductive
and developmental effects, has been raised based on results from
animal toxicity studies with certain low molecular weight phtha-
lates. In rats, application of high doses of di-n-butylphthalate (DBP)
and DEHP during speciﬁc phases of pregnancy induce reproductive
toxicity in male offspring (EFSA, 2005a; EFSA, 2005b; EFSA, 2005c;
EFSA, 2005d; EFSA, 2005e). The effects include malformations of
the epididymis, vas deferens, seminal vesicles, prostate, external
genitalia (hypospadias) and cryptorchidism, as well as retention of
nipples/areola (sexually dimorphic structure in rodents) and
demasculinization of the perineum resulting in a reduction in
anogenital distance (AGD). This pattern is sometimes termed the
“phthalate syndrome” and is speculated as similar to a human
disease termed ‘testicular dysgenesis syndrome’ (TDS). TDS in
humans is hypothesized (Juul et al., 2014; Main et al., 2010; Sharpe
and Skakkebaek, 2008) to account for many common disorders of
newborn (such as cryptorchidism and hypospadias) and young
adult males (such as low sperm count and testicular germ cell
cancers) but the mode of action and underpinnings of TDS are
unclear,. This concern on phthalates has raised a discussion on
safety regarding many applications and resulted in national stra-
tegies regarding replacement of phthalates in commerce. However,
the reproductive toxicity of low to medium molecular weight
phthalates is different with clear effects observed for DEHP, DBP,
and di(isobutyl)phthalate (DiBP) in one- and/or multigeneration
studies (EFSA, 2005a; EFSA, 2005b; EFSA, 2005c; EFSA, 2005d;
EFSA, 2005e; EU-RAR, 2008) whereas high molecular weight
phthalates such as diisononylphthalate (DINP) and diisodecylph-
thalate (DIDP) did not induce such effects and reproductive toxicity
is not considered a concern with dimethyl (DMP) and diethylph-
thalate (DEP) (Anonymous,1997; Field et al., 1993; Gray et al., 2000;
Hushka et al., 2001; SCCP, 2007; Waterman et al., 1999, 2000).
The purpose of the application of a QWOE to the toxicity data-
base on DINP, DCHP, and DnHP was to assess the robustness of the
QWOE-methodology and the relevance of reported effects in the
scientiﬁc literature in a transparent, consistent and scientiﬁcally
justiﬁed way, using predetermined scores for quality and rele-
vance/effects. DnHP and DCHP have harmonized classiﬁcations
according to the CLP regulation as category 1B reproductive toxi-
cants (DnHP for both development and fertility; DCHP only for
development), while, according to the European Risk Assessment
report (EU-RAR, 2003), a classiﬁcation of DINPwas notmandated at
the time of the preparation of the EU-RAR. Since completion of the
EU RAR, little new information on the effects of DINP on repro-
ductive endpoints has been generated and is integrated here.
2. Methods
In the ﬁrst step, potentially useful publications for assessment
purposes on the animal toxicology of DINP, DCHP, and DnHP were
searched with a cut-off date of July 31, 2015. To capture all publi-
cations and minimize search-bias, the literature search included
PubMed, TOXLINE, Chemical Abstracts, and SciFinder with the
following search terms:
 CAS # 84-61-7 (DCHP), CAS # 84-75-3 (DnHP), CAS # 28553-12-
0, and CAS # 68515-48-0 (both DINPs) in “ToxLine”,
 CAS # 84-61-7, CAS # 84-75-3, CAS # 28553-12-0, and CAS #
68515-48-0 and “toxicity” in “Chemical abstracts”
 CAS # 84-61-7, CAS # 84-75-3, CAS # 28553-12-0, and CAS #
68515-48-0 and “toxicity” in “PubMed”
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68515-48-0 and “toxicity” in “SciFinder”
All publications identiﬁed by these searches are listed in Annex
1 provided as supplementary material. The results of the literature
search were compared to reports and publications listed in the EU
risk assessment report on DINP (EU-RAR, 2003). In addition, orig-
inal study reports of guideline studies on DINP were available.
Current understanding of the biology and modes of action involved
in reproductive toxicology was obtained from appropriate text-
books and reviews (Gupta, 2011; Klaassen, 2013). Abstracts of all
publications identiﬁed in the literature searchwere read. To narrow
the focus of the evaluations, all publications that did not address
results from animal toxicity studies on the phthalates of interest
were not further considered. All animal toxicity studies were then
screened to identify if they addressed endpoints relevant to
reproductive toxicity in their design and effects assessment (see
below for details). Only publications that fulﬁlled this criterion
were evaluated further. The detailed methodology including
detailed scoring criteria for study quality and relevance/effects can
be found in Dekant and Bridges (2016). In brief, the developed
QWoE methodology utilizes numerical scoring to assess reliability
of a publication and the toxicological relevance of reported effects.
Scores are given for fourteen quality aspects, best practice receives
the highest score. The relevance/effects scores (0 to four) are
adjusted to the key elements of the toxic response for the endpoint
and include weighting factors for effects on different levels of
biological organization. The relevance/effects scores are then
assessed against the criteria dose-response, magnitude and
persistence of effects, consistency of observations with the hy-
pothesis, and relation of effects to human disease. The quality/
reliability scores and the relevance/effect scores are thenmultiplied
to give a numerical strength of evidence for adverse effects. This
total score is then used to assign the chemical to the different
classes employed in classiﬁcation (Dekant and Bridges, 2016).
3. Results
3.1. Application of the QWoE-methodology to the database
The QWoE methodology was used to score all available publi-
cations for quality/reliability of results and for relevance/strength of
effects. Scoring sheets were deﬁned as described (Dekant and
Bridges, 2016). The quantitative scores were derived for fourteen
aspects relevant to quality, with the best practice for each speciﬁc
aspect receiving the highest score of four. A relevance of effect score
was given for each observation in a study. This score consisted of
two parts, a nature of effect score that places different weights on
the various types of observations based on their biological prox-
imity to an apical outcome and a strength of evidence score con-
sisting of ﬁve criteria aimed at quantifying the toxicological
signiﬁcance of the observation (Dekant and Bridges, 2016). The
quality scores and the relevance/strength of effects scores were
multiplied to give a numerical strength of evidence for adverse
effects on reproduction and on fertility. The total score for each
publication was brought together as a conclusion of the total
database for each chemical of interest and used to assign each
chemical to the different classes employed in classiﬁcation (ECHA,
2015). The results are presented in a table submitted as Annex 2
in the supplementary material.
Because the details of the developed score sheets were novel,
and there was no prior experience of their use, it was crucial to
conduct independent assessments for a range of the publications to
compare the scoring results. To check consistency in the scoring, 18
publications (ten for DINP, four for DCHP, and four for DnHP) wereindependently scored by both authors. A good general agreement
for both quality and relevance/strength scores was documented
(for a tabulated overview of the initial scoring, see Annex 2). Quality
and relevance/strength of effect scores only differed by app. 20%
and neither assessor had a general tendency to assign higher or
lower scores than the other. This demonstrates that criteria speci-
ﬁed in the scoring sheets are interpreted identically by both as-
sessors. In those few studies where there were substantial
variations, the scoring guidance sheets were re-reviewed to iden-
tify the cause of discrepancies. Once this was completed, double
scoring of all available papers on DINP, DCHP and DnHP was not
considered necessary and only one assessor (WD) scored all
studies. The few studies not scored by JB are indicated by NS in
Annex 2.
3.2. Conclusions on the overall strength of evidence to support a Cat
1B or 2 for reproductive and developmental toxicity according to
CLP for DINP, DCHP, and DnHP
To develop conclusions regarding support for classiﬁcation and
labeling, general developmental/reproductive effects and effects on
fertility were treated separately because the regulation on classi-
ﬁcation separates these endpoints. The QWoE presented here is
quantitative and is developed speciﬁcally for application to hazard
classiﬁcation mandated by EC regulation 1272/2008 (EC-
Regulation, 2008) on classiﬁcation, labeling and packaging of sub-
stances and mixtures (i.e the CLP Regulation or CLP).
3.2.1. Studies addressing developmental effects
General developmental toxicity was addressed by studies
investigating effects of DINP, DCHP and DnHP in offspring including
those with a follow-up of offspring until adulthood after in utero
exposure. The database thus included ten studies on DINP, ﬁve
studies on DCHP, and four studies on DnHP (Table 1). For studies on
developmental toxicity of DINP, the quality scores ranged from 2.0
to 3.79 (Table 1). For both DCHP and DnHP, average quality scores
were in the same range as for DINP, the databases on DCHP and
DnHP are much more limited with only few high quality studies
available (Table 1). It may be concluded that the available databases
on DINP, DCHP, and DnHP have an acceptable average quality but
individual study quality varies widely. High quality scores were
assigned to studies where the animal model was appropriate,
adequate numbers of animals/dose group were used with suitable
dose spacing and timing, concurrent controls were examined, in-
formationwas provided on historic controls, pathological and gross
assessments were properly performed (e.g. demonstrated expertise
and blinded readings/measurements), and the statistical evaluation
was appropriate (Clewell et al., 2013a, 2013b; Exxon, 1994, 1996a,
1996b; Waterman et al., 1999; Waterman et al., 2000).
Lower scores regarding quality were usually due to combina-
tions of the following issues:
 No access to raw data/only limited data provided
 major weaknesses in study design or execution, such as low
numbers of animals/dose group and/or inappropriate timing of
dosing or sampling
 inadequate characterization of the test chemicals and their
concentration and stability in the application medium
 limited or absent descriptions of quality control and measure-
ment methodology.
 absence of measures taken to avoid contamination from
potentially interfering chemicals
 inadequate assessment of maternal toxicity (only maternal
weight gain was determined in many studies, despite informa-
tion that hepatotoxicity may occur with the studied phthalates
Table 1
Overview on studies assessing potential adverse effects on development in animals for DINP, DCHP and DnHP used for ﬁnal scoring regarding level of evidence of adverse
effects (NS ¼ not scored). The table includes scoring of all publications identiﬁed in the literature search addressing developmental endpoints.
Publication Quality JB Quality WD Effects JB Effects WD Overall score JB Overall score WD
Summary of scores for DINP papers and reports
(Boberg et al., 2011) 2.29 2.14 34.00 40.00 77.86 85.60
(Clewell et al., 2011a; Clewell et al., 2013b) 3.54 3.79 37.50 33.00 132.75 125.07
(Clewell et al., 2011b; Clewell et al., 2013a) 3.28 3.57 21.00 29.00 68.88 103.53
(Masutomi et al., 2003) 2.92 2.15 49.00 64.00 143.08 137.60
(Exxon, 1996a) NS 3.58 NS 16.00 NS 57.28
(Exxon, 1996b) 3.36 3.75 24.00 16.00 80.64 60.00
(Exxon, 1994) 3.09 3.45 10.5 6.00 32.45 20.70
(Hellwig et al., 1997) NS 3.45 NS 0.00 NS 0.00
(Li et al., 2015) 2.08 2.07 26.00 71.00 54.08 146.97
(Gray et al., 2000) 2.60 2.57 48.00 66.00 124.80 169.62
Average overall score 2.90 3.05 31.25 34.10 89.32 90.64
Summary of scores for DCHP papers and reports
(Saillenfait et al., 2009b) 3.08 3.38 51.00 24.00 157.08 81.12
(Aydogan Ahbab and Barlas, 2013) 2.08 1.79 72.50 115.50 150.80 206.75
(Aydogan Ahbab and Barlas, 2015) 2.15 1.86 72.00 84.50 154.80 157.17
(Hoshino et al., 2005) 2.86 3.21 96.00 109.50 274.56 351.50
(Yamasaki et al., 2009) NS 2.77 NS 90.50 NS 250.69
Average overall score 2.54 2.60 72.88 84.80 184.31 209.44
Summary of scores for DnHP papers and reports
(Saillenfait et al., 2009b) 3.09 3.23 186.00 193.00 574.74 623.39
(Saillenfait et al., 2009a) 3.08 3.38 139.00 160.50 428.12 542.49
(Aydogan Ahbab and Barlas, 2013) 2.08 1.79 72.50 108.50 150.80 194.22
(Aydogan Ahbab and Barlas, 2015) 2.15 1.86 72.00 90.00 154.80 167.40
Average overall score 2.60 2.57 117.38 138.00 327.12 381.87
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2013)
Relevance/effects scores were developed based on the effects
reported in the studies and include weighting factors for effects on
different levels of biological organization. In the QWoE-approach,
weighted endpoints were checked against the criteria dose-
response, magnitude and persistence of effects, consistency of ob-
servations with the hypothesis, and relation of effects to human
disease (Dekant and Bridges, 2016). Detailed results of the QWoE-
evaluation are given in the scoring sheets in Annex 3. Relevance/
effect scores regarding developmental effects for DINP ranged from
zero to 71, relevance/effects scores for DCHP ranged from 24 to
115.5, and from 72 to 193 for DnHP (Table 1).
3.2.2. Scoring for effects on fertility
Regarding fertility, the following types of studies were
considered:
 exposure of both male and female animals over at least two
weeks before mating and during the mating period.
 consequences of in utero exposures in offspring after reaching
adulthood.
 “classical” repeated dose studies assessing reproductive organ
function and histopathology.
The database evaluated included ﬁve studies on DINP, three
studies on DCHP, and three studies on DnHP. Thus, the number of
studies assessing fertility endpoints for the three phthalates of in-
terest was more limited compared to those assessing develop-
mental effects. The results of the scoring for quality and relevance/
strengths of effects of all studies addressing fertility endpoints are
summarized in Table 2. Individual scoring sheets are detailed in
Annex 3. Aswith the studies on developmental effects, based on the
scoring for quality, the available databases on DINP, DCHP, and
DnHP are generally of acceptable quality. Again, the quality of the
individual studies varies widely, In common with the develop-
mental effects, relevance/strength of effects scores were highlydifferent for the three phthalates of interest with DINP receiving
low effects scores while DnHP had high effect scores due to clear
adverse effects.
A plot of quality scores versus relevance/effects scores gives a
graphical overview on the results of the QWoE and permits an
assessment of distribution of scores and potential uncertainties
(Figs. 1 and 2). When comparing the score plots for developmental
effects (top chart, Fig. 1), it is evident that most high quality studies
do not provide any evidence for adverse effects of DINP on devel-
opment since the highest quality studies consistently received
relevance/effects scores well below 50. The database remains
consistent when integrating all studies with an acceptable quality
(score above 2). The more limited database on developmental ef-
fects for DCHP (center, Fig. 1) shows an acceptable quality for most
studies, but a larger spread of relevance/effects scores with several
high quality studies reaching scores of 100 and above. For DnHP
(lower chart, Fig. 1), quality is also acceptable for most studies with
two high quality studies receiving relevance/effect scores of >150.
Plots of the scoring regarding fertility also consistently show no
evidence for adverse effects from the studies on DINP with the
highest quality studies receiving very low scores for relevance/ef-
fects (Fig. 2, top chart). The databases on DCHP and DnHP regarding
the endpoint fertility are more limited (Fig. 2, center and bottom
chart) and show a larger spread of quality scores due to the pres-
ence of studies with lower reliability with DCHP receiving top
scores of >100 and one high quality study on DnHP with a score of
>200 indicating strong evidence for adverse effects.
4. Discussion
The criteria in the CLP Regulation (EC Regulation 1272/2008
1272/2008 part 3.7) were used as a basis for conclusions based on
the QWoE regarding C&L of DINP, DCHP, and DnHP (Dekant and
Bridges submitted manuscript). According to the classiﬁcation
criteria, classiﬁcation has to be based on the induction of adverse
effects in appropriately performed animal toxicity studies. How-
ever, according to the guidance, even in the presence of adverse
effects, classiﬁcation is not appropriate if:
Table 2
Overview on studies assessing potential adverse effects on fertility in animals for DINP, DCHP and DnHP used for ﬁnal scoring regarding level of evidence of adverse effects
(NS ¼ not scored). The table includes scoring of all publications identiﬁed in the literature search addressing fertility.
Publication Quality JB Quality WD Effects JB Effects WD Overall score JB Overall score WD
Summary of scores for DINP papers and reports
(Boberg et al., 2011) 2.29 2.14 15.00 6.00 34.35 12.84
(Masutomi et al., 2003) 2.92 2.15 52.00 69.50 151.84 149.43
(Kwack et al., 2009) 2.18 2.00 32.50 10.50 70.85 21.00
(Exxon, 1996a) NS 3.58 NS 0.00 NS 0.00
(Exxon, 1996b) 3.36 3.75 16.50 0.00 55.44 0.00
Average overall score 2.69 2.72 29.00 17.20 78.12 36.65
Summary of scores for DCHP papers and reports
(Aydogan Ahbab and Barlas, 2013) 2.08 1.79 125.00 96.00 260.00 171.84
(Hoshino et al., 2005) 2.86 3.21 92.50 60.50 264.55 194.21
(Yamasaki et al., 2009) NS 2.77 NS 67.50 NS 186.98
Average overall score 2.47 2.59 108.75 74.67 262.28 184.34
Summary of scores for DnHP papers and reports
(Aydogan Ahbab and Barlas, 2013) 2.08 1.79 125.00 87.50 260.00 156.63
(Lamb et al., 1987) NS 3.00 NS 208.00 NS 624.00
(Foster et al., 1980) NS 2.00 NS 64.50 NS 129.00
Average overall score 2.08 2.26 125.00 120.00 260.00 303.21
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ondary consequence of other toxic effects (e.g. due to
maternal toxicity).
ii) There is an adequate number of studies but insufﬁcient
strength of evidence when considered together (3.7.2.3.1).
iii) Differences in toxicokinetics are so marked that it is certain
that hazardous effects seen in the animal model will not be
seen in man (3.7.2.3.2, 3.72.5.8).
iv) Mode of action differences are so marked that it is certain
that hazardous effects seen in the animal model will not be
seen in man (3.7.2.3.3).
v) The effects observed are considered to be of low or minimum
signiﬁcance (e.g. small changes in semen parameters, small
changes in the incidence of spontaneous defects in the fetus
(3.7.2.3.3).
vi) The study uses exposure levels above the limit dose (how-
ever, there is no clear deﬁnition but 1000 mg/kg bw/day is
indicated as a benchmark in 3.7.2.5.7 of the guidelines).
WoE-approaches are included in the CLP Regulation (3.7.2.3.1)
which state that “the weight given to the available evidence will be
inﬂuenced by factors such as the quality of the studies, consistency
of results, nature and severity of effects, the presence of maternal
toxicity in experimental animal studies, level of statistical signiﬁ-
cance for inter-group differences, number of endpoints affected,
relevance of route of administration to humans and freedom from
bias. Both positive and negative results are assembled together into
a weight of evidence determination.” These essential issues are
addressed by the QWoEmethodology. Level of evidence for adverse
effects is obtained by the scoring for relevance/strength of effects
and addresses points i, ii, v, and vi outlined above.
Regarding conclusions on C&L, the overall strength of evidence
obtained by a multiplication of the quality and relevance/strength
scores is applied with numerical limits deﬁned based on level of
evidence (Dekant and Bridges, 2016). For chemicals where all
studies have an overall weight of evidence score below 245, there is
insufﬁcient evidence of the induction of adverse effects and
therefore no scientiﬁc basis for classiﬁcation as a reproductive
toxicant. Overall scores between 246 and 350 indicate limited ev-
idence for adverse effects thus supporting a classiﬁcation as a
category 2 reproductive toxicant. Overall scores above 351 conﬁrm
strong evidence for induction of adverse effects and a classiﬁcation
as a category 1B reproductive toxicant (Dekant and Bridges, 2016).
One issue with deriving overall weight of evidence scores is the
large range of endpoints assessed by the individual studies in alarger database. For the three phthalates assessed here, some
studies only assessed biochemical parameters or observed minor
changes with an unknown relation to adverse effects while others
performed a comprehensive assessment of potential adverse ef-
fects. Scores for these studies are contained in Annex 2. Studies
limited to biochemical parameters receive low relevance/effects
scores. Inevitably, inclusion of studies with a limited scope that
results in a low relevance/effects score will bias the summary re-
sults towards lower scores. For example, if the studies addressing
only biochemical effects were to be included in the summary
scores, this decreases the overall weight of evidence score from
90.64 (Table 1) to 68.24 (for WD who scored all studies), from
209.44 (WD) to 176.54 for DCHP, and from 381.87 (WD) to 273.38
for DnHP. It was therefore decided to exclude studies with very
limited relevance/effects scores (Adamsson et al., 2009; Borch et al.,
2004; Furr et al., 2014; Kwack et al., 2009) from calculating an
overall weight of evidence score.
For DINP, all overall weight of evidence scores for development
and the overall weight of evidence scores for all individual studies
(Fig. 3) remain well below the threshold for “limited evidence to
support induction of adverse effects” (Dekant and Bridges, 2016).
Scores for adverse developmental effects of DCHP and DnHP both
for individual studies and the overall weight of evidence scores
(Fig. 3) are much higher. For DCHP, the overall score for effects on
development remains below the threshold for “limited evidence”,
but scores for one study by one of the assessors reaches the
threshold for “strong evidence” with two additional scores sup-
porting “limited evidence” (Fig. 3, top chart). DnHP reached an
overall score above the threshold to conclude on “good evidence”
for adverse developmental effects (Fig. 3, top chart). For fertility
endpoints (Fig. 3, lower chart), all scores for DINP also provide no
evidence of adverse effects. Overall, the database for DCHP also
does not provide evidence for an adverse effect on fertility,
although the strength of evidence scores for one study just passes
the threshold for “limited evidence”. The scoring of effects of DnHP
on fertility on average (Fig. 3, lower chart) only supports “limited
evidence for an adverse effect”. However, one of the high quality
publications on DnHP indicates “good/strong evidence of an
adverse effect”. Effects observed in this study are consistent with
observations made with other low to medium molecular weight
phthalates, are biologically plausible and consistent with the hy-
pothesis. Therefore, the QWoE supports a classiﬁcation of DnHP
into category 1b for fertility.
In summary, the QWoE evaluation showed clear differences in
the overall scores between DINP and the benchmark chemicals
Fig. 1. Plot of quality/reliability scores versus relevance/effect scores for the outcome
of the QWoE assessment of all studies addressing developmental endpoints of DINP,
DCHP, and DnHP. Figure includes means ± SD of scores for each of the phthalates.
Fig. 2. Plot of quality/reliability scores versus relevance/effect scores for the outcome
of the QWoE assessment of all studies addressing fertility endpoints of DINP, DCHP, and
DnHP. Figure includes means ± SD of scores for each of the phthalates.
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of evidence, there is no biologically justiﬁed support for an
assignment of a CLP reproductive classiﬁcation category for DINP.
Using a conservative approach, the QWoE supports a classiﬁcation
of DCHP as a category 1B reproductive toxicant regarding devel-
opmental effects due to scores above the threshold for one good
quality study and no support for classiﬁcation on fertility. However,
based on the overall weight of evidence scoring, category 2 for
development is considered more appropriate. The outcome of the
QWoE for DnHP well supports the existing classiﬁcation for DnHP
as category 1b reproductive toxicant regarding both development
and fertility.4.1. Comparison of the results of the QWoE with narrative
assessments for DINP
For a further validation of the QWoE approach, a comparison ofthe outcome of the QWoE with a detailed narrative approach
regarding effects reported in the databases on DINP, DCHP, and
DnHP is detailed below.
4.1.1. Developmental effects
The available DINP animal toxicity studies show that a “clas-
sical” narrative approach well supports the conclusions from the
QWoE. DINP (Waterman et al., 1999, 2000) does not cause any of
the permanent effects that have been observed with short and
medium chain phthalates (EFSA, 2005a). For example, malforma-
tions and permanent histopathological changes of the male
reproductive tract were not observed. Effects on reproductive or-
gans in newer studies (Boberg et al., 2011; Clewell et al., 2013a,
2013b) were only transient, did not persist to adulthood, and
occurred at doses levels where a number of other studies with DINP
have demonstrated maternal toxicity. Moreover, some of the effects
such as AGD and nipple retention (Boberg et al., 2011) are only
signiﬁcant at the p < 0.05 level and reported the dose-dependency
Fig. 3. Distribution of strength of evidence score for DINP , DCHP , and DnHP for
developmental (top chart) and fertility endpoints (bottom chart) and relation to
thresholds regarding strength of evidence and basis for classiﬁcation. Limited evidence
to support the hypothesis of induction of adverse effects requires a minimum score of
246 and strong evidence a minimum score of 350. Limited evidence supports a clas-
siﬁcation as a category 2 reproductive toxicant and strong evidence supports a clas-
siﬁcation as a category 1B reproductive toxicant.
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bioavailability at doses > 300 mg/kg bw (Clewell et al., 2013a).
Therefore, it appears unlikely that the reported changes are related
to an increase in foetal exposure to DINP or DINP-metabolites.
An increased incidence of “malformations” following DINP
administration was only reported in one study with DINP (Gray
et al., 2000), but statistical signiﬁcance was only reached when
the different types of effects were summed for statistical analysis.
This is inappropriate. In addition, this study reported an increase in
areolae at PND13 (22.4% in DINP-treated animals as compared to an
incidence of 0% in controls), but a later study from the same labo-
ratory reported an areolae incidence of 14% in controls (Ostby et al.,
2001). Both studies were evaluated regarding consequences for
classiﬁcation (EU-RAR, 2003) and were not considered as providing
information to warrant classiﬁcation.
The toxicological signiﬁcance of the reversible induction of
multinucleated germ cells (MNGs) (Boberg et al., 2011; Clewell
et al., 2011a, 2011b) DINP is unclear. Reduced testicular testos-
terone levels are unlikely to be involved in the etiology of MNG
formation in rats (Scott et al., 2007). MNGs are also apparently not
formed by proliferative events (Spade et al., 2015). In summary,
these ﬁndings suggest that MNG formation is not androgen
dependent and thus may not represent an endpoint that is
consistent with the hypothesis that an interference with testos-
terone in rats is a key effect in the reproductive toxicity of some
phthalates. Moreover, the increased incidences of MNGs apparently
have no functional consequences (Waterman et al., 1999, 2000).
Thus, they do not qualify as being adverse. Nonetheless, in the
QWoE assessment developed, these observations were included in
the weighted scores. The available DINP developmental toxicity
studies also showed some increases in the incidences of minor
skeletal variations at maternally toxic dose levels, but noabnormalities were reported. Likely, these variations are induced
by maternal effects of the very high doses of DINP. The available
developmental toxicity studies were evaluated in the EU-RAR in
2003 with the conclusion “Regarding …. development, the effects
observed in the available studies, do not justify classiﬁcation according
to the EU classiﬁcation criteria”. The QWoE demonstrates that this
conclusion remains valid.
4.1.2. Effects on fertility
Effects of DINP on fertility-related parameters were only re-
ported in two studies (Boberg et al., 2011; Kwack et al., 2009).
Kwack et al., 2009 reported signiﬁcantly lowered sperm counts and
motility of epididymal sperm after a four-week treatment of adult
rats with a single dose level of 500 mg DINP/kg bw/day by daily
gavage. The study suffers from the use of a single dose level and
unclear reporting regarding use of concurrent controls. Moreover,
the changes in sperm number only had a statistical signiﬁcance
level of <0.05 and general toxicity of DINP has been reported to
occur at dose levels above ~200 mg/kg bw/day (ECHA/RAC, 2013).
The limited information provided (Kwack et al., 2009) also indicates
treatment-related general toxicity such as body weight reduction,
increases in relative organweights, effects on clinical chemistry and
hematology parameters. Thus, the effects on sperm count and
sperm motility may be secondary to systemic toxicity.
Boberg et al., 2011 assessed reproductive parameters in male
rats exposed in utero to doses of up to 900 mg DINP/kg bw/day.
Sperm analysis at PND90 showed an increase in sperm count only
the highest dose and a statistically signiﬁcant, but not dose-related
decrease in sperm motility at the 600, 750, and 900 mg/kg bw/day.
Testes weights and histology were unaffected at PND 90. The study
has several limitations. Sperm analyses examined only 1e3 animals
per litter and sperm motility in control was low and the changes
noted in the DINP-treated groups remained within the range of
historical controls (Jarfelt et al., 2005; Taxvig et al., 2007). Accord-
ing to the guidance (OECD, 2008), in general, 200 sperm should be
analyzed and a minimum value of 70% motility is acceptable in
controls. Further, dose-response and changes in testes histology are
required to determine whether an effect is considered to be
adverse. Testes histology is considered the most sensitive endpoint
indicative of adverse effects of chemicals on male fertility
(Mangelsdorf et al., 2003). Therefore, the information presented
regarding sperm motility is inconclusive. The absence of effects on
development and fertility in the two-generation reproductive and
developmental toxicity study (Waterman et al., 2000) does not
support the effects of DINP on fertility. While the design of these
studies does not speciﬁcally address early life effects onmale sexual
development, it is noted that DEHP and other lowmolecular weight
phthalates did cause persistent adverse effects on male reproduc-
tive performance in similar studies (EFSA, 2005a; EFSA, 2005c).
While some of the available 90-day toxicity studies with DINP re-
ported some effects on male reproductive organ weight, these ef-
fects occurred at much higher doses than those causing
hepatotoxicity (the former ECB deﬁned 276 mg/kg bw/day as
NOAEL for effects of DINP on reproductive organweight changes as
compared to liver toxicity for which the NOAEL for liver effects of
DINP has been identiﬁed by ECHA as 15 mg/kg bw/day). In sum-
mary regarding fertility, changes reported in the individual studies
with DINP were inconsistent regarding incidences and periods of
observed changes and no permanent changes were observed.
Therefore, the transient effects seen (Boberg et al., 2011) do not
qualify as “adverse” regarding “sexual function and fertility”. It is
therefore evident that there is no “clear evidence of an adverse effect
on sexual function… in the absence of other toxic effects” and a
classiﬁcation of DINP into Cat. 1B or 2 according to CLP is neither
supported by a narrative approach nor by the QWoE applied here.
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that states that “small changes in semen parameters or in the
incidence of spontaneous defects in the fetus, small changes in the
proportions of common fetal variants such as are observed in
skeletal examinations, or in fetal weights, or small differences in
postnatal developmental assessments” cannot be used to justify
classiﬁcation.
4.2. Comparison of the results of the QWoE with narrative
assessments for DCHP
4.2.1. Developmental effects
For DCHP, only ﬁve studies on developmental toxicity endpoints
are available. The average scores from the QWoE do not support a
classiﬁcation as a category 2 developmental toxicant. However, an
individual study received a score of 274.56 by one assessor and of
351.5 by the other assessor, which is at the borderline for classiﬁ-
cation as category 1b (score of 351 and above). The low overall
weight of evidence score of the database on DCHP regarding
developmental effects is mainly due to the low scoring of two
publications (Aydogan Ahbab and Barlas, 2013; Aydogan Ahbab and
Barlas, 2015) that investigated relevant endpoints for DCHP and
observed a number of changes that can be considered as adverse.
However, the changes were observed at all dose levels of DCHP
without an obvious dose-response despite applying a 25-fold
spread between the tested doses (20 mg/kg/day to 500 mg/
kg bw/day) and occurred at dose levels where neither of the two
other more comprehensive studies (Hoshino et al., 2005; Saillenfait
et al., 2009a) report DCHP-induced changes when compared to
concurrent controls. However, when assessed individually, Hoshino
et al., 2005 reports changes in reproductive organ weights and
AGD/nipple development in male F1 and F2 pups. The 2nd high
quality study for reproductive effects of DCHP (Saillenfait et al.,
2009a) observed very limited effects for this endpoint due to the
study focus on developmental changes and was not included in the
overall weight of evidence scoring. In summary, the high scores of
the high quality study support category1B when applying a con-
servative approach.
4.2.2. Effects on fertility
Of the three studies addressing fertility aspects of DCHP, only
one can be considered of good quality. Only one QWoE score,
264.55 by one assessor, is above the threshold (246) suggesting
“limited evidence” for an adverse effect on fertility. The overall
score, however, remains well below “limited evidence”. Hoshino
et al., 2005 did not observe clear effects on fertility parameters in
the two-generation study and only noted an approx. 20% decrease
in homogenization resistant spermatids in the F1 parental gener-
ation, apparently without functional consequences. Yamasaki et al.,
2009 describes the presence of decreased testicular germ cells in
animals sacriﬁced at ten weeks of age in the high dose group of
500mg DCHP/kg bw/day, but gives neither data on incidences nor a
statistical evaluation (Yamasaki et al., 2009). Therefore, classiﬁca-
tion regarding fertility is not supported for DCHP by a narrative
assessment.
4.3. Comparison of the results of the QWoE with narrative
assessments for DnHP
4.3.1. Developmental effects
Only two studies were identiﬁed as high quality (Saillenfait
et al., 2009a, 2009b). Both studies report a series of adverse ef-
fects that were persistent up to 14 weeks of age and thus support a
classiﬁcation regarding developmental effects as category 1b. The
high scores of these two animal studies (>500) also indicate clearevidence of adverse effects in studies relevant for classiﬁcation and
labeling purposes. A 3rd study (Saillenfait et al., 2013) only assessed
changes in testosterone and expression of proteins involved in
steroid biosynthesis. The data in this study show a clear dose-
dependent reduction of testicular testosterone (in contrast to
data on DINP) and changes in steroid biosynthesis gene expression.
These ﬁndings are consistent with the above conclusion; however,
the study did not assess adverse changes. The overall score
regarding developmental effects of DnHP again is reduced due to
the two studies with a lower quality assignment (Aydogan Ahbab
and Barlas, 2013; Aydogan Ahbab and Barlas, 2015). However, the
clear effects on development well support a category 1B for
development.
4.3.2. Effects on fertility
Work by the US NTP (published as Lamb et al., 1987) reports a
marked effect of high doses of DnHP-administration on fertility in
mice. In addition, Saillenfait et al. (2009b) also reports clear and
permanent effects of DnHP-administration on reproductive organ
histopathology. Moreover, short term administration of DnHP for 4
days has been shown to induce marked effects on testes weight in
the absence of effects on body weight (Foster et al., 1980). There-
fore, the narrative assessment of effects relevant to C&L for DnHP is
consistent with the outcome of the QWoE assessment.
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